Long-Term Outcome of Radiotherapy for Early Stage Dupuytren’s Disease: A Phase III Clinical Study

2011 ◽  
pp. 349-371 ◽  
Author(s):  
Michael Heinrich Seegenschmiedt ◽  
Ludwig Keilholz ◽  
Mark Wielpütz ◽  
Christine Schubert ◽  
Fabian Fehlauer
Keyword(s):  
Clinical Study ◽  
Early Stage ◽  
Phase Iii ◽  
Dupuytren’S Disease ◽  
Term Outcome ◽  
Dupuytren's Disease ◽  
Long Term Outcome

What patients want from the treatment of Dupuytren’s disease — is the Unité Rhumatologique des Affections de la Main (URAM) scale relevant?

2014 ◽  
Vol 40 (2) ◽  
pp. 150-154 ◽  
Author(s):  
J. N. Rodrigues ◽  
W. Zhang ◽  
B. E. Scammell ◽  
T. R. C. Davis
Keyword(s):  
Face Validity ◽  
Dupuytren’S Disease ◽  
Level Of Evidence ◽  
Term Outcome ◽  
Dupuytren's Disease ◽  
Long Term Outcome ◽  
Specific Outcome ◽  
Disease Specific Outcome Measure ◽  
The Uk

Patients awaiting surgery for Dupuytren’s contractures listed the problems from their Dupuytren’s disease that had led them to request surgery and their relative priorities of the results of surgery. The listed problems were compared with the nine items comprising the Unité Rhumatologique des Affections de la Main (URAM) Dupuytren’s disease-specific outcome measure. One hundred and ten patients reported 278 problems. Ninety-four different combinations of problems were provided by patients, and over half (55%) of the problems were not captured by items in the URAM scale. The long-term outcome from surgery was relatively more important to patients than speed of recovery. The URAM tool may not be relevant to patients in the UK, and further assessment of its face validity is required before it is used. Level of evidence: III

scholarly journals ESMO 2020: highlights in breast cancer

2021 ◽  
Author(s):  
Rupert Bartsch
Keyword(s):  
Breast Cancer ◽  
Early Stage ◽  
Phase Iii ◽  
Long Term Results ◽  
High Risk Population ◽  
Her2 Positive ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Early Results

SummaryDespite the ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, results of several pertinent studies in the field of breast cancer (BC) were presented in a virtual format at the 2020 European Society of Medical Oncology (ESMO) Congress. Early results of the MonarchE trial investigating the addition of the cyclin-dependent kinase (CDK) 4/6 inhibitor abemaciclib to standard adjuvant endocrine therapy indicated a lower recurrence rate in the combination group in a high-risk population of patients with early stage hormone receptor (HR)-positive/HER2-negative BC. In contrast, the PALLAS study evaluating adjuvant palbociclib could not confirm these results. Subtle differences in the respective trial populations, a higher discontinuation rate in PALLAS, or substance-specific differences may be responsible. In HER2-positive early stage BC, long-term results of the ADAPT-TP trial support the notion that chemotherapy-free treatment may be possible in a subset of patients with favourable response to HER2-directed therapy without compromising long-term outcome. The phase III IMpassion031 trial evaluated the addition of atezolizumab to neoadjuvant anthracycline/taxane-containing chemotherapy in triple-negative BC (TNBC). A significant improvement in terms of pathologic complete remission rate was observed but data concerning long-term outcome must be awaited. Final overall survival (OS) analysis of IMpassion130 confirmed the clinically relevant OS improvement observed with the addition of atezolizumab to first-line nab-paclitaxel in metastatic PD-L1 positive TNBC. In contrast, no benefit was observed with the addition of atezolizumab to solvent-based paclitaxel in a similar population. This contradiction is commonly explained by the need for corticosteroid co-medication with conventional paclitaxel, but the exact reason remains poorly understood. Antibody–drug conjugates (ADCs) have been successfully established in HER2-positive breast cancer; in TNBC, the phase III ASCENT trial compared the ADC sacituzumab govitecan with chemotherapy by physician’s choice in pretreated metastatic patients. A significant improvement in terms of progression-free survival and OS was observed rendering this drug a potential novel standard in this patient population.

scholarly journals Long-term Outcome of Involved Node Radiation Therapy for Early Stage Hodgkin Lymphoma

2018 ◽  
Vol 102 (3) ◽  
pp. S123
Author(s):  
K. Nielsen ◽  
M.V. Maraldo ◽  
M.C. Aznar ◽  
P.M. Petersen ◽  
I. Vogelius ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Hodgkin Lymphoma ◽  
Early Stage ◽  
Term Outcome ◽  
Long Term Outcome

Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin's Disease Collaborative Group.

1998 ◽  
Vol 16 (3) ◽  
pp. 830-843 ◽  
Author(s):  
L Specht ◽  
R G Gray ◽  
M J Clarke ◽  
R Peto
Keyword(s):  
Hodgkin's Disease ◽  
Randomized Trials ◽  
Early Stage ◽  
Hodgkin’S Disease ◽  
Survival Rates ◽  
Collaborative Group ◽  
Mortality Data ◽  
Term Outcome ◽  
Long Term Outcome

PURPOSE To assess the effect of more extensive radiotherapy and of adjuvant combination chemotherapy on long-term outcome of early-stage Hodgkin's disease. METHODS In a collaborative worldwide systematic overview, individual patient data were centrally reviewed on 1,974 patients in eight randomized trials of more versus less extensive radiotherapy and on 1,688 patients in 13 trials of radiotherapy plus chemotherapy versus radiotherapy alone. Crude mortality data on 226 patients in two other trials of chemotherapy were also reviewed. RESULTS More extensive radiotherapy reduced the risk of treatment failure (resistant or recurrent disease) at 10 years by more than one third (31.3% v 43.4% failures; P < .00001), but there was no apparent improvement in overall 10-year survival (77.1 % v 77.0% alive). The addition of chemotherapy to radiotherapy halved the 10-year risk of failure (15.8% v 32.7%; P < .00001), with a small, nonsignificant improvement in survival (79.4% v 76.5% alive). This involved a reduction of borderline significance for deaths from Hodgkin's disease (12.3% v 15.4% dead at 10 years; P = .07), which was partly counterbalanced by a nonsignificant excess of deaths from other causes (12.4% v 10.0% 10-year risk). CONCLUSION More extensive radiotherapy fields or the addition of chemotherapy to radiotherapy in the initial treatment of early-stage Hodgkin's disease had a large effect on disease control, but only a small effect on overall survival. Recurrences could be prevented by more extensive radiotherapy or by additional chemotherapy. However, if chemotherapy had not been given initially, recurrences were generally salvageable by re-treatment with chemotherapy. Hence, less intensive primary treatment--particularly a reduction in radiotherapy fields--appears to achieve similar survival rates as more intensive treatment, although more randomized evidence is needed to confirm this.

Involved node radiation therapy in the combined modality treatment for early-stage Hodgkin lymphoma: Analysis of relapse location and long-term outcome

2020 ◽  
Vol 150 ◽  
pp. 236-244
Author(s):  
Karin Nielsen ◽  
Maja Vestmoe Maraldo ◽  
Anne Kiil Berthelsen ◽  
Annika Loft ◽  
Peter de Nully Brown ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Hodgkin Lymphoma ◽  
Early Stage ◽  
Combined Modality Treatment ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Combined Modality

scholarly journals Galectin-3 as a Next-Generation Biomarker for Detecting Early Stage of Various Diseases

Biomolecules ◽  
2020 ◽  
Vol 10 (3) ◽  
pp. 389 ◽  
Author(s):  
Akira Hara ◽  
Masayuki Niwa ◽  
Kei Noguchi ◽  
Tomohiro Kanayama ◽  
Ayumi Niwa ◽  
...  
Keyword(s):  
Early Stage ◽  
Biological Activities ◽  
Biological Fluids ◽  
Inflammatory Cells ◽  
Tumor Formation ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Galectin 3 ◽  
Binding Lectin

Galectin-3 is a β-galactoside-binding lectin which is important in numerous biological activities in various organs, including cell proliferation, apoptotic regulation, inflammation, fibrosis, and host defense. Galectin-3 is predominantly located in the cytoplasm and expressed on the cell surface, and then often secreted into biological fluids, like serum and urine. It is also released from injured cells and inflammatory cells under various pathological conditions. Many studies have revealed that galectin-3 plays an important role as a diagnostic or prognostic biomarker for certain types of heart disease, kidney disease, viral infection, autoimmune disease, neurodegenerative disorders, and tumor formation. In particular, it has been recognized that galectin-3 is extremely useful for detecting many of these diseases in their early stages. The purpose of this article is to review and summarize the recent literature focusing on the biomarker characteristics and long-term outcome predictions of galectin-3, in not only patients with various types of diseases, but associated animal models.

Long-Term Outcome of Percutaneous Ablation in Very Early-Stage Hepatocellular Carcinoma

2011 ◽  
Vol 15 (12) ◽  
pp. 2165-2171 ◽  
Author(s):  
Ming Kuang ◽  
Xiao-Yan Xie ◽  
Cheng Huang ◽  
Ye Wang ◽  
Man-Xia Lin ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Early Stage ◽  
Percutaneous Ablation ◽  
Term Outcome ◽  
Long Term Outcome

Psychosocial functioning in relation to symptomatic remission: A longitudinal study of first episode schizophrenia

2015 ◽  
Vol 30 (8) ◽  
pp. 907-913 ◽  
Author(s):  
K. Jaracz ◽  
K. Górna ◽  
J. Kiejda ◽  
B. Grabowska-Fudala ◽  
J. Jaracz ◽  
...  
Keyword(s):  
Social Functioning ◽  
Psychosocial Functioning ◽  
Early Stage ◽  
First Episode ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Poor Outcome ◽  
Remission Status ◽  
Symptomatic Remission

AbstractObjectivesThe aims of the study were: (1) to evaluate longitudinally symptomatic remission in first-episode (FE) schizophrenia, (2) to describe symptoms, social functioning and quality of life (Qol) in relation to remission status, and (3) to determine the long-term outcome of schizophrenia and its early predictors.MethodsSixty-four patients were assessed 1 month after a first hospitalization (T1), 12 months (T2), 4–6 years (T3), and 7–11 years (T4) after T1. The patients were allocated to three remission groups according to their remission status over the whole observation period, e.g. stable remission (SR), unstable remission (UR) and non-remission (NR). The PANSS, Social Functioning Scale and WHOQoL were used to evaluate the patients’ psychosocial functioning levels, symptomatic and functional remissions and satisfying QoL. A good outcome was defined as meeting, simultaneously, the criteria of symptomatic and functional remissions and satisfying QoL at T4, while failure to meet all of these criteria was defined as a poor outcome.ResultsAmong them, 17.2% patients were in stable remission, 57.8% in unstable remission and 25.0% were unremitted at all time points. The SR group had lower levels of psychopathological symptoms and reported better social functioning and QoL than the NR group. During the follow-up, the symptoms increased, social functioning slightly improved and QoL did not change. At T4, 53% of the sample had a poor outcome, which was independently predicted by the longer duration of untreated psychosis and a lack of satisfying QoL at T1.ConclusionsOur results demonstrate that: (1) the long-term course in schizophrenia is heterogeneous and that three illness trajectories exist, (2) social functioning and QoL are only partially connected with symptomatic remission (3), the risk of a poor outcome may potentially be reduced by appropriate interventions at an early stage of the illness.

Sign in / Sign up

Export Citation Format

Share Document